Search results :

Nelarabine

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01BB07

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2
Neutropenia 14% - 94% x x
Thrombocytopenia 22% - 88% x x
Anaemia 10% - 99% x x
Leukopenia 7% - 38% x x
Fatigue 2% - 50% x x
Febrile neutropenia 1% - 12% x x
Dizziness 0% - 21% x x
Blood bilirubin increased 2% - 10% x
Body temperature increased 0% - 23% x x
Pleural effusion 1% - 10% x x
Muscular weakness 0% - 8% x x
Blood albumin decreased 1% - 10% x
Pneumonia 1% - 8% x x
Transaminases increased 0% - 12% x x
Blood glucose decreased 0% - 6% x
Blood potassium decreased 2% - 11% x
Headache 0% - 17% x x
Dehydration 1% - 7% x
Dyspnoea 0% - 20% x x
Hypoaesthesia 0% - 17% x x
Pain 0% - 11% x x
Peripheral sensory neuropathy 0% - 13% x
Infection postmarketing, 1% - 9% x x
Confusional state 0% - 8% x x
Nervous system disorder postmarketing, 0% - 21% x x
Neuropathy peripheral postmarketing, 0% - 6% x x
Petechiae 0% - 12% x
Blood magnesium decreased 0% - 6% x
Somnolence 0% - 23% x x
Paraesthesia 0% - 15% x x
Tremor 0% - 5% x x
Peripheral motor neuropathy 0% - 7% x
Abdominal pain 0% - 9% x x
Amnesia 0% - 3% x x
Arthralgia 0% - 9% x x
Asthenia 0% - 17% x x
Ataxia 0% - 9% x x
Constipation 0% - 21% x x
Depression 0% - 6% x
Diarrhoea 0% - 22% x x
Dysgeusia 0% - 3% x x
Hyperglycaemia 0% - 6% x
Hypotension 1% - 8% x x
Pain in extremity 0% - 7% x x
Sinusitis 0% - 7% x
Stomatitis 0% - 8% x x
Sinus tachycardia 0% - 8% x
Aspartate aminotransferase increased 1% - 6% x x
Myalgia 0% - 13% x x
Motor dysfunction 0% - 4% x
Non-cardiac chest pain 0% - 5% x
Depressed level of consciousness 0% - 6% x
Balance disorder 0% - 2% x x
Blood calcium decreased 1% - 8% x
Vomiting 0% - 22% x x
Demyelination postmarketing x x
Guillain-Barre syndrome postmarketing x x
Opportunistic infection postmarketing x x
Rhabdomyolysis postmarketing x x
Tumour lysis syndrome postmarketing x x
Malnutrition postmarketing x x
Infestation NOS postmarketing x x
Blood creatine phosphokinase increased postmarketing x x
Abdominal distension 0% - 6% x
Anorexia 0% - 9% x x
Aphasia x
Back pain 0% - 8% x x
Bacteraemia x
Mental disorder x x
Metabolic encephalopathy x
Chest pain 0% - 5% x
Coma x
Connective tissue disorder x x
Cough 0% - 25% x x
Cyst x
Dysarthria x
Oedema 0% - 15% x x
Grand mal convulsion 0% - 1% x
Epistaxis 0% - 8% x
Eye disorder x
Gastrointestinal disorder x x
Cardiac disorder x
Blood disorder x x
Hemiparesis x
Hydrocephalus x
Hyperbilirubinaemia x
Hypocalcaemia x
Hypoglycaemia x
Hypokalaemia x
Lethargy x
Chronic lymphocytic leukaemia x
Progressive multifocal leukoencephalopathy x x
Mediastinal disorder x x
Hypertonia x
Fungal infection x
Nausea 0% - 41% x x
Neoplasm x
Neuralgia x
Nystagmus x
Pneumothorax x
Polyp x
Sciatica x
Convulsion 0% - 6% x x
Sinus headache x
Speech disorder x
Status epilepticus 0% - 1% x x
Loss of consciousness x
Urinary tract disorder x
Angiopathy x x
Wheezing 0% - 5% x x
Encephalopathy x
Burning sensation x
Oedema peripheral x
Haemorrhage intracranial x
Hypomagnesaemia x
Hyporeflexia x
Sensory disturbance x
Respiratory arrest x
Disturbance in attention x
Neurotoxicity x
Blood creatinine increased 0% - 6% x x
Sepsis x
Nerve paralysis x
Hepatobiliary disease x x
Leukoencephalopathy x
Peroneal nerve palsy x
Sensory loss 0% - 2% x
Pneumonia fungal x
Vision blurred x x
Rigors 0% - 8% x
Neuropathy 0% - 4% x
Coordination abnormal x
Paralysis x
Gait disturbance x
Hyperuricaemia x
Blood and lymphatic system disorders x x
Insomnia 0% - 7% x
Mental disability x
Cerebral haemorrhage x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

nelarabine / nelarabine

Side effects:81
Source:EMA

NELARABINE

Side effects:123
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label